ABSTRACT
BACKGROUND: We describe the first case of a pediatric patient with acute intermittent porphyria and severe chronic porphyric neuropathy treated with givosiran, a small-interfering RNA that drastically decreases delta-aminolevulinic acid production and reduces porphyric attacks' recurrence. CASE REPORT: A 12-year-old male patient with refractory acute intermittent porphyria and severe porphyric neuropathy was followed prospectively for 12 months after givosiran initiation (subcutaneous, 2.5 mg/kg monthly). Serial neurological, structural, and resting-state functional magnetic resonance imaging (MRI) evaluations were performed, including clinical scales and neurophysiological tests. Delta-aminolevulinic acid urinary levels dropped drastically during treatment. In parallel, all the administered neurological rating scales and neurophysiological assessments showed improvement in all domains. Moreover, an improvement in central motor conduction parameters and resting-state functional connectivity in the sensory-motor network was noticed. At the end of the follow-up, the patient could walk unaided after using a wheelchair for 5 years. CONCLUSIONS: A clear beneficial effect of givosiran was demonstrated in our patient with both clinical and peripheral nerve neurophysiologic outcome measures. Moreover, we first reported a potential role of givosiran in recovering central motor network impairment in acute intermittent porphyria (AIP), which was previously unknown. This study provides Class IV evidence that givosiran improves chronic porphyric neuropathy.
Subject(s)
Acetylgalactosamine/analogs & derivatives , Porphyria, Acute Intermittent , Humans , Male , Porphyria, Acute Intermittent/drug therapy , Child , Acetylgalactosamine/therapeutic use , Aminolevulinic Acid/analogs & derivatives , Aminolevulinic Acid/urine , Magnetic Resonance Imaging , Pyrrolidines/therapeutic use , Uridine/analogs & derivatives , Uridine/therapeutic use , Uridine/administration & dosage , Recovery of Function , Chronic Disease , Treatment OutcomeABSTRACT
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults. Commercial arrangement There is a simple discount patient access scheme for vutrisiran. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact info@alnylam.co.uk for details.
Subject(s)
Humans , Adult , Amyloid Neuropathies, Familial/drug therapy , Acetylgalactosamine/therapeutic use , Prealbumin/therapeutic useABSTRACT
Small interfering ribonucleic acids [siRNAs] are short ribonucleic acid (RNA) fragments cleaved from double-stranded RNA molecules that target and bind to specific sequences on messenger RNA (mRNA), leading to their destruction. Therefore, the siRNA down-regulates the formation of selected mRNAs and their protein products. Givosiran is one such siRNA that uses this mechanism to treat acute hepatic porphyrias. Acute hepatic porphyrias are a group of rare, inherited metabolic disorders, characterized by acute potentially life-threatening attacks as well as chronic symptoms with a negative impact on quality of life. It has four types, each associated with distinct enzyme defects in the heme biosynthesis pathway in the liver. By targeting the expression of hepatic 5-aminolevulinic acid [ALA] synthase-1 [ALAS1], givosiran can down-regulate levels of toxic metabolites, leading to biochemical and clinical improvement. Givosiran selectively targets hepatocytes due to its linkage to N-acetylgalactosamine (GalNac) leading to its selective uptake via asialoglycoprotein receptors (ASGPR). We provide an up-to-date literature review regarding givosiran in the context of a clinical overview of the porphyrias, an overview of siRNAs for therapy of human disorders, the design and development of givosiran, key clinical trial results of givosiran for prevention of acute porphyric attacks, emerging concerns regarding chronic use of givosiran, and the overall management of acute hepatic porphyrias. These insights are important not only for the management of acute hepatic porphyrias but also for the emerging field of siRNAs and their role in novel therapies for various diseases.
Subject(s)
Acetylgalactosamine , Porphyrias, Hepatic , Acetylgalactosamine/analogs & derivatives , Acetylgalactosamine/therapeutic use , Adult , Humans , Porphobilinogen Synthase/deficiency , Porphyrias, Hepatic/diagnosis , Porphyrias, Hepatic/drug therapy , Porphyrias, Hepatic/genetics , Pyrrolidines , Quality of Life , RNA, Messenger/metabolism , RNA, Small Interfering/therapeutic useABSTRACT
Givosiran is a small synthetic double-stranded siRNA (small interfering RNA) conjugated with N-acetyl-galactosamine (GalNAc) for specific hepatocyte targeting via the asialoglycoprotein receptor. A prospective randomized multicenter study (Envision) demonstrated the clinical efficacy of monthly subcutaneous injection of Givosiran for the prevention of attacks of acute hepatic porphyria (AHP). This leads to highly selective transcriptional inhibition of the key hepatic enzyme, aminolaevulinate synthase 1, that is overexpressed in AHP. The success of the Envision study has led to the approval of Givosiran in the US and Europe for the treatment of severe AHP. This innovative guided siRNA therapy has opened up the possibility to selectively inhibit the expression of any hepatocyte gene whose overexpression that causes pathology, which can be considered a milestone development in hepatology. However, currently this treatment with givosiran is very costly. Moreover, since some patients experience worsening of kidney function and elevated aminotransferases, monthly monitoring of these parameters is necessary in the first half year of treatment.
Subject(s)
Acetylgalactosamine/analogs & derivatives , Porphobilinogen Synthase/deficiency , Porphyrias, Hepatic/drug therapy , Pyrrolidines , RNA, Small Interfering , RNAi Therapeutics , 5-Aminolevulinate Synthetase/antagonists & inhibitors , Acetylgalactosamine/administration & dosage , Acetylgalactosamine/therapeutic use , Humans , Porphobilinogen Synthase/metabolism , Porphyrias, Hepatic/metabolism , Porphyrias, Hepatic/physiopathology , Porphyrias, Hepatic/prevention & control , Pyrrolidines/administration & dosage , Pyrrolidines/therapeutic use , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/therapeutic use , RNA, Small Interfering/ultrastructure , Randomized Controlled Trials as TopicABSTRACT
The increasing number of approved nucleic acid therapeutics demonstrates the potential to treat diseases by targeting their genetic blueprints in vivo. Conventional treatments generally induce therapeutic effects that are transient because they target proteins rather than underlying causes. In contrast, nucleic acid therapeutics can achieve long-lasting or even curative effects via gene inhibition, addition, replacement or editing. Their clinical translation, however, depends on delivery technologies that improve stability, facilitate internalization and increase target affinity. Here, we review four platform technologies that have enabled the clinical translation of nucleic acid therapeutics: antisense oligonucleotides, ligand-modified small interfering RNA conjugates, lipid nanoparticles and adeno-associated virus vectors. For each platform, we discuss the current state-of-the-art clinical approaches, explain the rationale behind its development, highlight technological aspects that facilitated clinical translation and provide an example of a clinically relevant genetic drug. In addition, we discuss how these technologies enable the development of cutting-edge genetic drugs, such as tissue-specific nucleic acid bioconjugates, messenger RNA and gene-editing therapeutics.
Subject(s)
Genetic Vectors/therapeutic use , Nanoparticles/therapeutic use , Nucleic Acids/therapeutic use , Acetylgalactosamine/analogs & derivatives , Acetylgalactosamine/therapeutic use , Gene Editing/methods , Gene Expression Regulation/drug effects , Genetic Vectors/genetics , Genetic Vectors/pharmacology , Humans , Lipids/chemistry , Nanoparticles/chemistry , Nucleic Acids/administration & dosage , Nucleic Acids/pharmacology , Oligonucleotides/therapeutic use , Oligonucleotides, Antisense/therapeutic use , Pyrrolidines/therapeutic use , RNA, Small Interfering/chemistry , RNA, Small Interfering/therapeutic useABSTRACT
Givosiran is a novel approach to treat patients with acute intermittent porphyrias (AIP) by silencing of ∂-ALA-synthase 1, the first enzyme of heme biosynthesis in the liver. We included two patients in the Envision study who responded clinically well to this treatment. However, in both patients, therapy had to be discontinued because of severe adverse effects: One patient (A) developed local injection reactions which continued to spread all over her body with increasing number of injections and eventually caused a severe systemic allergic reaction. Patient B was hospitalized because of a fulminant pancreatitis. Searching for possible causes, we also measured the patients plasma homocysteine (Hcy) levels in fluoride-containing collection tubes: by LC-MS/MS unexpectedly, plasma Hcy levels were 100 and 200 in patient A and between 100 and 400 µmol/l in patient B. Searching for germline mutations in 10 genes that are relevant for homocysteine metabolism only revealed hetero- and homozygous polymorphisms in the MTHFR gene. Alternatively, an acquired inhibition of cystathionine-beta-synthase which is important for homocysteine metabolism could explain the plasma homocysteine increase. This enzyme is heme-dependent: when we gave heme arginate to our patients, Hcy levels rapidly dropped. Hence, we conclude that inhibition of ∂-ALA-synthase 1 by givosiran causes a drop of free heme in the hepatocyte and therefore the excessive increase of plasma homocysteine. Hyperhomocysteinemia may contribute to the adverse effects seen in givosiran-treated patients which may be due to protein-N-homocysteinylation.
Subject(s)
5-Aminolevulinate Synthetase/antagonists & inhibitors , Acetylgalactosamine/analogs & derivatives , Heme/deficiency , Hyperhomocysteinemia/etiology , Porphyria, Acute Intermittent/drug therapy , Pyrrolidines/therapeutic use , Acetylgalactosamine/adverse effects , Acetylgalactosamine/therapeutic use , Adult , Arginine/therapeutic use , Colitis/etiology , Colon, Sigmoid/pathology , Controlled Clinical Trials as Topic , Drug Hypersensitivity/etiology , Female , Fibrosis , Heme/analysis , Heme/therapeutic use , Hepatocytes/drug effects , Hepatocytes/metabolism , High-Throughput Nucleotide Sequencing , Homocysteine/metabolism , Humans , Hydroxymethylbilane Synthase/blood , Hydroxymethylbilane Synthase/genetics , Male , Models, Biological , Pancreatitis/etiology , Porphyria, Acute Intermittent/blood , Porphyria, Acute Intermittent/complications , Porphyria, Acute Intermittent/genetics , Pyrrolidines/adverse effectsABSTRACT
BACKGROUND AND AIMS: RO7062931 is an N-acetylgalactosamine (GalNAc)-conjugated single-stranded locked nucleic acid oligonucleotide complementary to HBV RNA. GalNAc conjugation targets the liver through the asialoglycoprotein receptor (ASGPR). This two-part phase 1 study evaluated the safety, pharmacokinetics, and pharmacodynamics of RO7062931 in healthy volunteers and patients with chronic hepatitis B (CHB) who were virologically suppressed. APPROACH AND RESULTS: Part 1 was a single ascending dose study in healthy volunteers randomized to receive a single RO7062931 dose (0.1-4.0 mg/kg), or placebo. Part 2 was a multiple ascending dose study in patients with CHB randomized to receive RO7062931 at 0.5, 1.5, or 3.0 mg/kg or placebo every month for a total of 2 doses (Part 2a) or RO7062931 at 3.0 mg/kg every 2 weeks, 3.0 mg/kg every week (QW), or 4.0 mg/kg QW or placebo for a total of 3-5 doses (Part 2b). Sixty healthy volunteers and 59 patients received RO7062931 or placebo. The majority of adverse events (AEs) reported were mild in intensity. Common AEs included self-limiting injection site reactions and influenza-like illness. Supradose-proportional increases in RO7062931 plasma exposure and urinary excretion occurred at doses ≥3.0 mg/kg. In patients with CHB, RO7062931 resulted in dose-dependent and time-dependent reduction in HBsAg versus placebo. The greatest HBsAg declines from baseline were achieved with the 3.0 mg/kg QW dose regimen (mean nadir ~0.5 log10 IU/mL) independent of HBeAg status. CONCLUSIONS: RO7062931 is safe and well tolerated at doses up to 4.0 mg/kg QW. Supradose-proportional exposure at doses of 3.0-4.0 mg/kg was indicative of partial saturation of the ASGPR-mediated liver uptake system. Dose-dependent declines in HBsAg demonstrated target engagement with RO7062931.
Subject(s)
Acetylgalactosamine/therapeutic use , Hepatitis B, Chronic/drug therapy , Oligonucleotides, Antisense/therapeutic use , Oligonucleotides/therapeutic use , Acetylgalactosamine/analogs & derivatives , Adult , Asialoglycoprotein Receptor , Female , Healthy Volunteers , Hepatitis B Surface Antigens/blood , Hepatitis B virus/genetics , Hepatitis B, Chronic/blood , Humans , Male , Middle Aged , Oligonucleotides/genetics , Oligonucleotides, Antisense/genetics , RNA, Viral/genetics , Sustained Virologic ResponseABSTRACT
Small interfering RNA (siRNA)-based therapeutics holds the promise to treat a wide range of human diseases that are currently incurable using conventional therapies. Most siRNA therapeutic efforts to date have focused on the treatment of liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver. Indeed, the development of lipid nanoparticle-formulated and GalNAc-conjugated siRNA therapeutics has resulted in recent FDA approvals of the first siRNA-based drugs, patisiran for the treatment of hereditary transthyretin amyloidosis and givosiran for the treatment of acute hepatic porphyria, respectively. Here, we describe the current strategies for delivering siRNA drugs to the liver and summarize recent advances in clinical development of siRNA therapeutics for the treatment of liver diseases.
Subject(s)
Liver Diseases/therapy , RNA Interference , RNA, Small Interfering/therapeutic use , RNAi Therapeutics , Acetylgalactosamine/analogs & derivatives , Acetylgalactosamine/therapeutic use , Amyloid Neuropathies, Familial/genetics , Amyloid Neuropathies, Familial/metabolism , Amyloid Neuropathies, Familial/therapy , Animals , Gene Transfer Techniques , Humans , Liver Diseases/genetics , Liver Diseases/metabolism , Porphyrias, Hepatic/diagnosis , Porphyrias, Hepatic/metabolism , Porphyrias, Hepatic/therapy , Pyrrolidines/therapeutic use , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolismABSTRACT
Acute intermittent porphyria (AIP) is a rare metabolic disease caused by mutations within the hydroxymethylbilane synthase gene. Previous studies have reported increased levels of plasma total homocysteine (tHcy) in symptomatic AIP patients. In this study, we present long-term data for tHcy and related parameters for an AIP patient cohort (n = 37) in different clinical disease-states. In total, 25 patients (68%) presented with hyperhomocysteinemia (HHcy; tHcy > 15 µmol/L) during the observation period. HHcy was more frequent in AIP patients with recurrent disease receiving heme arginate, than in nonrecurrent (median tHcy: 21.6 µmol/L; range: 10-129 vs median tHcy: 14.5 µmol/L; range 6-77). Long-term serial analyses showed a high within-person tHcy variation, especially among the recurrent patients (coefficient of variation: 16.4%-78.8%). HHcy was frequently associated with low blood concentrations of pyridoxal-5'-phosphate and folate, while cobalamin concentration and the allele distribution of the methylene-tetrahydrofolate-reductase gene were normal. Strikingly, 6 out of the 9 recurrent patients who were later included in a regime of givosiran, a small-interfering RNA that effectively reduced recurrent attacks, showed further increased tHcy (median tHcy in 9 patients: 105 µmol/L; range 16-212). Screening of amino acids in plasma by liquid-chromatography showed co-increased levels of methionine (median 71 µmol/L; range 23-616; normal <40), suggestive of acquired deficiency of cystathionine-ß-synthase. The kynunerine/tryptophan ratio in plasma was, however, normal, indicating a regular metabolism of tryptophan by heme-dependent enzymes. In conclusion, even if HHcy was observed in AIP patients receiving heme arginate, givosiran induced an aggravation of the dysregulation, causing a co-increase of tHcy and methionine resembling classic homocystinuria.
Subject(s)
Acetylgalactosamine/analogs & derivatives , Arginine/deficiency , Heme/deficiency , Hyperhomocysteinemia/etiology , Porphyria, Acute Intermittent/drug therapy , Pyrrolidines/therapeutic use , Acetylgalactosamine/adverse effects , Acetylgalactosamine/therapeutic use , Adult , Arginine/therapeutic use , Cystathionine beta-Synthase/genetics , Female , Folic Acid/blood , Heme/therapeutic use , Homeostasis , Homocysteine/metabolism , Homocystinuria/complications , Humans , Hydroxymethylbilane Synthase/blood , Hydroxymethylbilane Synthase/genetics , Male , Methionine/blood , Middle Aged , Porphyria, Acute Intermittent/blood , Porphyria, Acute Intermittent/complications , Porphyria, Acute Intermittent/genetics , Pyridoxal Phosphate/blood , Pyrrolidines/adverse effects , Young AdultABSTRACT
Givosiran (Givlaari®) is an δ-aminolevulinic acid synthase 1 (ALAS1)-directed small interfering RNA (siRNA) approved for the treatment of acute hepatic porphyria (AHP). In the phase 3 ENVISION trial, givosiran significantly reduced the annualized rate of composite porphyria attacks (i.e. attacks requiring hospitalization, urgent healthcare visit or intravenous hemin administration at home) compared with placebo in patients with recurrent acute intermittent porphyria (the most common type of AHP) attacks. Givosiran also improved several other outcomes, including hemin use and pain (the cardinal symptom of AHP). While generally well tolerated with an acceptable safety profile, the drug may increase the risk of hepatic and kidney adverse events. Givosiran offers the convenience of once-monthly subcutaneous administration. Available evidence indicates that givosiran is an important newer therapeutic option for patients with AHP and severe recurrent attacks.
Subject(s)
Acetylgalactosamine/analogs & derivatives , Porphobilinogen Synthase/deficiency , Porphyria, Acute Intermittent/drug therapy , Porphyrias, Hepatic/drug therapy , Pyrrolidines/pharmacology , Pyrrolidines/therapeutic use , 5-Aminolevulinate Synthetase/antagonists & inhibitors , Acetylgalactosamine/adverse effects , Acetylgalactosamine/pharmacokinetics , Acetylgalactosamine/pharmacology , Acetylgalactosamine/therapeutic use , Acute Kidney Injury/chemically induced , Chemical and Drug Induced Liver Injury , Drug Interactions , Hemin/administration & dosage , Hospitalization , Humans , Pain/drug therapy , Pain/etiology , Porphyria, Acute Intermittent/complications , Porphyrias, Hepatic/complications , Pyrrolidines/adverse effects , Pyrrolidines/pharmacokinetics , RNA, Small Interfering , Randomized Controlled Trials as Topic , Severity of Illness IndexSubject(s)
Hemophilia A/therapy , Acetylgalactosamine/therapeutic use , Antibodies, Bispecific/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , COVID-19/complications , COVID-19/epidemiology , Disease Management , Hemophilia A/complications , Humans , RNA, Small Interfering/therapeutic useSubject(s)
Acetylgalactosamine/analogs & derivatives , Acetylgalactosamine/therapeutic use , Porphyria, Acute Intermittent/drug therapy , Pyrrolidines/therapeutic use , RNAi Therapeutics , Humans , Molecular Targeted Therapy , Porphyria, Acute Intermittent/diagnosis , Porphyria, Acute Intermittent/genetics , Treatment OutcomeABSTRACT
Hemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The recent development of new nonfactor replacement treatments and biotechnology techniques has offered therapeutic alternatives for hemophilia patients with and without inhibitors. These are characterized by an easier route of administration, low immunogenicity, and, regarding gene therapy and cell-based treatments, potential long-term protection from bleeding after a single treatment course. In this review, we analyze recent progresses in the management of hemophilia and discuss opportunities and challenges.
Subject(s)
Blood Coagulation Factors/therapeutic use , Hemophilia A/therapy , Hemophilia B/therapy , Hemorrhage/prevention & control , Acetylgalactosamine/administration & dosage , Acetylgalactosamine/pharmacology , Acetylgalactosamine/therapeutic use , Antibodies, Bispecific/administration & dosage , Antibodies, Bispecific/pharmacology , Antibodies, Bispecific/therapeutic use , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/pharmacology , Antibodies, Monoclonal, Humanized/therapeutic use , Blood Coagulation Factors/administration & dosage , Clinical Trials as Topic , Coagulants/administration & dosage , Coagulants/therapeutic use , Factor IX/administration & dosage , Factor IX/genetics , Factor IX/therapeutic use , Factor VIII/administration & dosage , Factor VIII/genetics , Factor VIII/therapeutic use , Genetic Therapy/methods , Hemophilia A/complications , Hemophilia A/genetics , Hemophilia B/complications , Hemophilia B/genetics , Hemorrhage/etiology , Hemorrhage/mortality , History, 20th Century , Humans , Infusions, Intravenous , Injections, Subcutaneous , Laboratories/statistics & numerical data , Life Expectancy/history , Life Expectancy/trends , Lipoproteins/administration & dosage , Lipoproteins/pharmacology , Lipoproteins/therapeutic use , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/pharmacology , RNA, Small Interfering/therapeutic use , Severity of Illness IndexABSTRACT
BACKGROUND: Up-regulation of hepatic delta-aminolevulinic acid synthase 1 (ALAS1), with resultant accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen, is central to the pathogenesis of acute attacks and chronic symptoms in acute hepatic porphyria. Givosiran, an RNA interference therapy, inhibits ALAS1 expression. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned symptomatic patients with acute hepatic porphyria to receive either subcutaneous givosiran (2.5 mg per kilogram of body weight) or placebo monthly for 6 months. The primary end point was the annualized rate of composite porphyria attacks among patients with acute intermittent porphyria, the most common subtype of acute hepatic porphyria. (Composite porphyria attacks resulted in hospitalization, an urgent health care visit, or intravenous administration of hemin at home.) Key secondary end points were levels of ALA and porphobilinogen and the annualized attack rate among patients with acute hepatic porphyria, along with hemin use and daily worst pain scores in patients with acute intermittent porphyria. RESULTS: A total of 94 patients underwent randomization (48 in the givosiran group and 46 in the placebo group). Among the 89 patients with acute intermittent porphyria, the mean annualized attack rate was 3.2 in the givosiran group and 12.5 in the placebo group, representing a 74% lower rate in the givosiran group (P<0.001); the results were similar among the 94 patients with acute hepatic porphyria. Among the patients with acute intermittent porphyria, givosiran led to lower levels of urinary ALA and porphobilinogen, fewer days of hemin use, and better daily scores for pain than placebo. Key adverse events that were observed more frequently in the givosiran group were elevations in serum aminotransferase levels, changes in serum creatinine levels and the estimated glomerular filtration rate, and injection-site reactions. CONCLUSIONS: Among patients with acute intermittent porphyria, those who received givosiran had a significantly lower rate of porphyria attacks and better results for multiple other disease manifestations than those who received placebo. The increased efficacy was accompanied by a higher frequency of hepatic and renal adverse events. (Funded by Alnylam Pharmaceuticals; ENVISION ClinicalTrials.gov number, NCT03338816.).
Subject(s)
Acetylgalactosamine/analogs & derivatives , Aminolevulinic Acid/urine , Porphobilinogen/urine , Porphyria, Acute Intermittent/drug therapy , Pyrrolidines/therapeutic use , RNAi Therapeutics , Acetylgalactosamine/adverse effects , Acetylgalactosamine/therapeutic use , Adult , Double-Blind Method , Fatigue/etiology , Female , Humans , Injections, Subcutaneous , Least-Squares Analysis , Liver/drug effects , Male , Nausea/etiology , Pain/etiology , Patient Outcome Assessment , Porphyria, Acute Intermittent/complications , Porphyria, Acute Intermittent/urine , Pyrrolidines/adverse effects , Renal Insufficiency, Chronic/chemically induced , Transaminases/bloodABSTRACT
RNA interference (RNAi) is an ancient biological mechanism used to defend against external invasion. It theoretically can silence any disease-related genes in a sequence-specific manner, making small interfering RNA (siRNA) a promising therapeutic modality. After a two-decade journey from its discovery, two approvals of siRNA therapeutics, ONPATTRO® (patisiran) and GIVLAARI™ (givosiran), have been achieved by Alnylam Pharmaceuticals. Reviewing the long-term pharmaceutical history of human beings, siRNA therapy currently has set up an extraordinary milestone, as it has already changed and will continue to change the treatment and management of human diseases. It can be administered quarterly, even twice-yearly, to achieve therapeutic effects, which is not the case for small molecules and antibodies. The drug development process was extremely hard, aiming to surmount complex obstacles, such as how to efficiently and safely deliver siRNAs to desired tissues and cells and how to enhance the performance of siRNAs with respect to their activity, stability, specificity and potential off-target effects. In this review, the evolution of siRNA chemical modifications and their biomedical performance are comprehensively reviewed. All clinically explored and commercialized siRNA delivery platforms, including the GalNAc (N-acetylgalactosamine)-siRNA conjugate, and their fundamental design principles are thoroughly discussed. The latest progress in siRNA therapeutic development is also summarized. This review provides a comprehensive view and roadmap for general readers working in the field.
Subject(s)
Acetylgalactosamine/analogs & derivatives , Genetic Diseases, Inborn/therapy , Pyrrolidines/therapeutic use , RNA, Small Interfering/therapeutic use , Acetylgalactosamine/genetics , Acetylgalactosamine/therapeutic use , Genetic Diseases, Inborn/genetics , Genetic Therapy/trends , Humans , RNA Interference , RNA, Double-Stranded/therapeutic use , RNA, Small Interfering/geneticsABSTRACT
Single-visit cures for chronic hepatitis C are lacking. We conducted two clinical studies towards the goal of developing a regimen for single-visit cure. In a randomized, open-label, Phase 2 study (RG101-04), investigators enrolled 26 adult chronic hepatitis C patients to evaluate safety and efficacy of single subcutaneous injection of RG-101 (4 mg/kg) and daily oral tablets of GSK2878175 (20 mg) for 6, 9 or 12 weeks. In another randomized, double-blind, single dose Phase 1 study (RG101-06), investigators enrolled 18 healthy men to assess safety and PK of GSK2878175 long-acting injectable at 100, 200 or 400 mg. In RG101-04, SVR48 rates were 50%, 56% and 89%, for the 6, 9 and 12 weeks treatment arms, respectively. All AEs were mild or moderate in severity (≤Grade 2). In RG101-06 at 400 mg, the mean duration of GSK2878175 plasma levels above in vitro therapeutic concentrations for GT1b was 41 days. All AEs were Grade 2 or less. In conclusion, single injection of RG-101 combined with 12 weeks of GSK2878175 oral tablets was generally well tolerated and resulted in high SVR rates in chronic hepatitis C patients. Single injections of GSK2878175 long-acting injectable were also well tolerated; however, higher doses would be required if used in combination with RG-101 to achieve the SVR rates observed in the oral combination study to enable a single-visit curative regimen.
Subject(s)
Acetylgalactosamine/analogs & derivatives , Antiviral Agents , Benzofurans , Hepatitis C, Chronic , Oligonucleotides , Acetylgalactosamine/therapeutic use , Adult , Antiviral Agents/therapeutic use , Benzofurans/therapeutic use , Double-Blind Method , Healthy Volunteers , Hepatitis C, Chronic/drug therapy , Humans , Male , Oligonucleotides/therapeutic use , Treatment OutcomeABSTRACT
In November 2019 givosiran became the second small interfering RNA (siRNA)-based drug to receive US Food and Drug Administration (FDA) approval, it has been developed for the treatment of acute intermittent porphyria (AIP), a disorder characterized by life-threatening acute neurovisceral attacks. The porphyrias are a group of disorders in which enzymatic deficiencies in heme production lead to toxic accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), which are involved in the neurovisceral attacks. Givosiran acts as a conventional siRNA to trigger RNA interference (RNAi)-mediated gene silencing on delta-ALA synthase 1 (ALAS1), thus returning ALA and PBG metabolites to the physiological level to attenuate further neurotoxicity. Givosiran makes use of a new hepatic-delivery system that conjugates three GalNac (N-acetylgalactosamine) molecules to the siRNA passenger strand. GalNac binds to the liver asialoglycoprotein receptor, favoring the internalization of these GalNac-conjugated siRNAs into the hepatic cells. In a phase I study, subcutaneous monthly administration of givosiran 2.5 mg/kg reduced > 90% of ALA and PBG content. This siRNA is being analyzed in ENVISION (NCT03338816), a phase III, multicenter, placebo-controlled randomized controlled trial. In preliminary results, givosiran achieved clinical endpoints for AIP, reducing urinary ALA levels, and presented a safety profile that enabled further drug development. The clinical performance of givosiran revealed that suppression of ALAS1 by GalNac-decorated siRNAs represents an additional approach for the treatment of patients with AIP that manifests recurrent acute neurovisceral attacks.